Cooperation between integrin ανβ3 and VEGFR2 in angiogenesis

Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273–286

Glade-Bender J et al (2003) VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 3:263–276

Ribatti D (2008) Napoleone Ferrara and the saga of vascular endothelial growth factor. Endothelium 15:1–8

Dass CR, Choong PF (2008) Cancer angiogenesis: targeting the heel of Achilles. J Drug Target 16:449–454

Andreoli CM, Miller JW (2007) Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 18:502–508

Papanas N, Maltezos E (2008) Advances in treating the ischaemic diabetic foot. Curr Vasc Pharmacol 6:23–28

Simo R et al (2006) Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2:71–98

Stupack DG, Cheresh DA (2004) Integrins and angiogenesis. Curr Top Dev Biol 64:207–238

Hynes RO (2002) A reevaluation of integrins as regulators of angiogenesis. Nat Med 8:918–921

Folkman J (2006) Angiogenesis. Annu Rev Med 57:1–18

Ingber DE, Folkman J (1989) Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. J Cell Biol 109:317–330

Cai W, Chen X (2006) Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 6:407–428

Alghisi GC, Ruegg C (2006) Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 13:113–135

Kumar CC (2003) Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 4:123–131

Plow EF et al (2000) Ligand binding to integrins. J Biol Chem 275:21785–21788

Herouy Y et al (2000) Autologous platelet-derived wound healing factor promotes angiogenesis via alphavbeta3-integrin expression in chronic wounds. Int J Mol Med 6:515–519

Leu SJ et al (2002) Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem 277:46248–46255

Brooks PC et al (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157–1164

Brooks PC et al (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569–571

Van WC (1995) Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Head Neck 17:140–147

Lim EH et al (2005) A review: integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis. Nanomedicine 1:110–114

Cai W et al (2008) Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des 14:2943–2973

Cai W et al (2008) Molecular imaging of tumor vasculature. Methods Enzymol 445:141–176

Hodivala-Dilke K (2008) alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. Curr Opin Cell Biol 20:514–519

Somanath PR et al (2009) Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem Biophys 53:53–64

D’Andrea LD et al (2006) Peptide-based molecules in angiogenesis. Chem Biol Drug Des 67:115–126

Lenz HJ (2005) Antiangiogenic agents in cancer therapy. Oncology (Williston Park) 19:17–25

Reynolds LE et al (2002) Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 8:27–34

Weis SM et al (2007) Cooperation between VEGF and beta3 integrin during cardiac vascular development. Blood 109:1962–1970

Eliceiri BP, Cheresh DA (2000) Role of alpha v integrins during angiogenesis. Cancer J 6(Suppl 3):S245–S249

Zhu J et al (2002) beta8 integrins are required for vascular morphogenesis in mouse embryos. Development 129:2891–2903

Proctor JM et al (2005) Vascular development of the brain requires beta8 integrin expression in the neuroepithelium. J Neurosci 25:9940–9948

Lakhe-Reddy S et al (2006) Beta8 integrin binds Rho GDP dissociation inhibitor-1 and activates Rac1 to inhibit mesangial cell myofibroblast differentiation. J Biol Chem 281:19688–19699

Mahabeleshwar GH et al (2006) Integrin signaling is critical for pathological angiogenesis. J Exp Med 203:2495–2507

Chew DP, Bhatt DL (2001) Oral glycoprotein IIb/IIIa antagonists in coronary artery disease. Curr Cardiol Rep 3:63–71

Maranian AM, Steinhubl SR (2002) Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction. Curr Cardiol Rep 4:313–319

Cannon CP (2003) Oral platelet glycoprotein IIb/IIIa receptor inhibitors—part II. Clin Cardiol 26:401–406

Rosove MH (2004) Platelet glycoprotein IIb/IIIa inhibitors. Best Pract Res Clin Haematol 17:65–76

Said SM et al (2007) Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment. Clin Res Cardiol 96:61–69

Maeshima Y et al (2002) Tumstatin an endothelial cell-specific inhibitor of protein synthesis. Science 295:140–143

Sudhakar A et al (2003) Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA 100:4766–4771

Mould AP et al (1998) Regulation of integrin function: evidence that bivalent-cation-induced conformational changes lead to the unmasking of ligand-binding sites within integrin alpha5 beta1. Biochem J 331((Pt 3)):821–828

Humphries MJ (2004) Monoclonal antibodies as probes of integrin priming and activation. Biochem Soc Trans 32:407–411

De S et al (2003) Molecular pathway for cancer metastasis to bone. J Biol Chem 278:39044–39050

Mahabeleshwar GH et al (2007) Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 101:570–580

Borges E et al (2000) Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J Biol Chem 275:39867–39873

Soldi R et al (1999) Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 18:882–892

Schneller M et al (1997) Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. EMBO J 16:5600–5607

Vuori K, Ruoslahti E (1994) Association of insulin receptor substrate-1 with integrins. Science 266:1576–1578

Doerr ME, Jones JI (1996) The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J Biol Chem 271:2443–2447

Falcioni R et al (1997) Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res 236:76–85

Folgiero V et al (2008) Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas. PLoS ONE 3:e1592

Wang JF et al (2001) Stimulation of beta 1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration. J Biol Chem 276:41950–41957

Napione L et al (2007) Integrins: a flexible platform for endothelial vascular tyrosine kinase receptors. Autoimmun Rev 7:18–22

Mahabeleshwar GH et al (2008) Integrin affinity modulation in angiogenesis. Cell Cycle 7:335–347

Masson-Gadais B et al (2004) Integrin alphavbeta3 requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones 8:37–52

Pampori N et al (1999) Mechanisms and consequences of affinity modulation of integrin alpha(V)beta(3) detected with a novel patch-engineered monovalent ligand. J Biol Chem 274:21609–21616

Byzova TV et al (2002) Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood 99:4434–4442

Ginsberg MH et al (2005) Integrin regulation. Curr Opin Cell Biol 17:509–516

Cheresh DA, Stupack DG (2008) Regulation of angiogenesis: apoptotic cues from the ECM. Oncogene 27:6285–6298

Arnaout MA et al (2007) Structure and mechanics of integrin-based cell adhesion. Curr Opin Cell Biol 19:495–507

Phillips DR et al (2001) Integrin tyrosine phosphorylation in platelet signaling. Curr Opin Cell Biol 13:546–554

Chandhoke SK et al (2004) Beta 3 integrin phosphorylation is essential for Arp3 organization into leukocyte alpha V beta 3-vitronectin adhesion contacts. J Cell Sci 117:1431–1441

Butler B et al (2003) Lig, -dependent activation of integrin alpha vbeta 3. J Biol Chem 278:5264–5270

Feng W (2008) The angiogenic response is dictated by beta3 integrin on bone marrow-derived cells. J Cell Biol 183:1145–1157

Johnson FM, Gallick GE (2007) SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 7:651–659

Kefalas P et al (1995) Signalling by the p60c-src family of protein-tyrosine kinases. Int J Biochem Cell Biol 27:551–563

Basson MD (2008) An intracellular signal pathway that regulates cancer cell adhesion in response to extracellular forces. Cancer Res 68:2–4

Coluccia AM et al (2008) Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 112:1346–1356

Eliceiri BP et al (1999) Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 4:915–924

Schwartzberg PL et al (1997) Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. Genes Dev 11:2835–2844

Lowell CA et al (1996) Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis. Blood 87:1780–1792

McHugh KP et al (2000) Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105:433–440

Soriano P et al (1991) Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693–702

Klinghoffer RA et al (1999) Src family kinases are required for integrin but not PDGFR signal transduction. EMBO J 18:2459–2471

Su X, Mi J et al (2008) RGT, a synthetic peptide corresponding to the integrin beta 3 cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin alpha IIb beta 3 with Src kinase. Blood 112:592–602

Stockmann C et al (2008) Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456:814–818

Jones PL et al (1997) Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol 139:279–293

Woodard AS et al (1998) The synergistic activity of alphavbeta3 integrin and PDGF receptor increases cell migration. J Cell Sci 111(Pt 4):469–478

Trusolino L et al (1998) Growth factor-dependent activation of alphavbeta3 integrin in normal epithelial cells: implications for tumor invasion. J Cell Biol 142:1145–1156

Rahman S et al (2005) Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells. BMC Cell Biol 6:8

Roskoski R Jr (2008) VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun 375:287–291

Igarashi KI et al (1998) Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2. Biochem Biophys Res Commun 246:95–99

Le Boeuf F et al (2004) Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J Biol Chem 279:39175–39185

Laramee M et al (2007) The scaffolding adapter Gab1 mediates vascular endothelial growth factor signaling and is required for endothelial cell migration and capillary formation. J Biol Chem 282:7758–7769

Graells J et al (2004) Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 123:1151–1161

Dardik R et al (2005) Molecular mechanisms underlying the proangiogenic effect of factor XIII. Arterioscler Thromb Vasc Biol 25:526–532

Dardik R et al (2006) Evaluation of the pro-angiogenic effect of factor XIII in heterotopic mouse heart allografts and FXIII-deficient mice. Thromb Haemost 95:546–550

Dardik R, Inbal A (2006) Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF. Exp Cell Res 312:2973–2982

Lee SC et al (2007) Autocrine VEGF signaling is required for vascular homeostasis. Cell 130:691–703

Chen J et al (2005) Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med 11:1188–1196

Somanath PR et al (2007) Akt1 signaling regulates integrin activation, matrix recognition, and fibronectin assembly. J Biol Chem 282:22964–22976

Wijelath ES et al (2006) Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res 99:853–860

Vlahakis NE et al (2007) Integrin alpha9beta1 directly binds to vascular endothelial growth factor (VEGF)-A and contributes to VEGF-A-induced angiogenesis. J Biol Chem 282:15187–15196

Becker PM et al (2005) Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. Circ Res 96:1257–1265

Pan Q et al (2007) Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem 282:24049–24056

Pellet-Many C et al (2008) Neuropilins: structure, function and role in disease. Biochem J 411:211–226

Qu CK (2002) Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response. Biochim Biophys Acta 1592:297–301

Maile LA, Clemmons DR (2002) Regulation of insulin-like growth factor I receptor dephosphorylation by SHPS-1 and the tyrosine phosphatase SHP-2. J Biol Chem 277:8955–8960

Ling Y et al (2003) Tyrosine phosphorylation of the beta3-subunit of the alphaVbeta3 integrin is required for membrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptor. Mol Endocrinol 17:1824–1833

Ling Y et al (2005) DOK1 mediates SHP-2 binding to the alphaVbeta3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells. J Biol Chem 280:3151–3158

Ling Y et al (2005) Role of SHPS-1 in the regulation of insulin-like growth factor I-stimulated Shc and mitogen-activated protein kinase activation in vascular smooth muscle cells. Mol Biol Cell 16:3353–3364

Clemmons DR et al (2007) Role of the integrin alphaVbeta3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress. Growth Horm IGF Res 17:265–270

Kwon M et al (2006) Recruitment of the tyrosine phosphatase Src homology 2 domain tyrosine phosphatase-2 to the p85 subunit of phosphatidylinositol-3 (PI-3) kinase is required for insulin-like growth factor-I-dependent PI-3 kinase activation in smooth muscle cells. Endocrinology 147:1458–1465

Edderkaoui M et al (2007) Insulin-like growth factor-I receptor mediates the prosurvival effect of fibronectin. J Biol Chem 282:26646–26655

Mitola S et al (2006) Type I collagen limits VEGFR-2 signaling by a SHP2 protein-tyrosine phosphatase-dependent mechanism 1. Circ Res 98:45–54

Lieskovska J et al (2006) The role of Src kinase in insulin-like growth factor-dependent mitogenic signaling in vascular smooth muscle cells. J Biol Chem 281:25041–25053

Chabot C et al (2009) New role for the protein tyrosine phosphatase DEP-1 in Akt activation and endothelial cell survival. Mol Cell Biol 29:241–253

Mattila E et al (2008) The protein tyrosine phosphatase TCPTP controls VEGFR2 signalling. J Cell Sci 121:3570–3580

Yamaoka-Tojo M et al (2006) IQGAP1 mediates VE-cadherin-based cell–cell contacts and VEGF signaling at adherence junctions linked to angiogenesis. Arterioscler Thromb Vasc Biol 26:1991–1997

Tzima E et al (2005) VE-cadherin links tRNA synthetase cytokine to anti-angiogenic function. J Biol Chem 280:2405–2408

Ukropec JA et al (2002) Regulation of VE-cadherin linkage to the cytoskeleton in endothelial cells exposed to fluid shear stress. Exp Cell Res 273:240–247